Home / Catalogue/ Growth recovery/ Hexarelin

Growth recoveryIn StockSubQ injection

Hexarelin

Hexapeptide · GHS-R agonist · 6 amino acids

Half-life

~1h

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

The STRONGEST growth hormone releasing peptide. Most potent GH release of all GHRPs. Also has cardioprotective properties. But significantly increases cortisol and prolactin. Desensitises quickly (4-6 weeks).

Mechanism of Action

Most potent GHRP for GH release. Also has direct cardiac protective effects (independent of GH). BUT raises cortisol/prolactin and desensitizes quickly.

Body vs. External Supply

🟢 Secretagogue (stimulates natural)

Brand / Trade Names

Examorelin (INN name) No commercial pharmaceutical brand Research peptide

Typical Research Dosage

100-200mcg per injection, 1-2x daily. Lower doses than other GHRPs due to potency.

Vial Duration Guide

2mg vial at 200mcg/day = 10 days. 5mg = 25 days.

Recommended Vial Size

★ 2mg vials At 200mcg/day, 2mg = 10 days ✓. Must cycle 4 wks on/off — smaller vials align with cycles. 10mg = 50 days ⚠️ exceeds shelf life AND cycle length.

Time to Effects

EARLY: 1-2 weeks FULL: 4-6 weeks (then desensitisation) Week 1: Strong GH pulse felt — tingling, flushing, hunger. More noticeable than milder GHRPs. Week 2-4: Rapid improvements in recovery and body composition. Strongest GHRP effect. Week 4-6: ⚠️ Desensitisation begins. Effects plateau and diminish. Must cycle off for 4+ weeks. This is a sprint, not a marathon. Use for 4-6 week bursts then switch to Ipamorelin or take a break.

Contraindications & Do Not Combine

• Do NOT combine with exogenous HGH • Do NOT combine with other GHRPs (GHRP-2, GHRP-6) — Hexarelin is already the strongest, stacking = excessive cortisol/prolactin • Monitor prolactin levels — may require management

Common Side Effects

Cortisol elevation (significant), prolactin elevation (significant), hunger, flushing, water retention, numbness/tingling

Drug Interactions

Somatostatin analogs, dopamine agonists

Reversibility

Reversible BUT: ⚠️ receptor desensitization occurs within 2-4 weeks of continuous use. Must cycle (2-4 weeks on, 2-4 weeks off).

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Ghigo et al. (1994) JCEM 78(3):693-8 — Potent GH release characterization • Deghenghi et al. (1994) Life Sci 54:1321-28 • NOT FDA APPROVED • Known for desensitization after 4-6 weeks continuous use • Significant prolactin elevation documented

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Reconstituted: 2-8°C, 14-21 days

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Hexarelin discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$55.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~1 hour
Delivery	SubQ injection
Typical dose	100-200mcg
Storage (lyoph.)	2–8°C
Storage (recon.)	4–6 weeks
Endogenous?	Secretagogue (stimulates natural)
Suppression	Mild cortisol/prolactin elevation
WADA	Prohibited (S2)
FDA status	Category 2 (2023)